Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects

NCT01999335 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01999335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01999335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Terminated
Start date
July 30, 2014
Completion date
April 25, 2019
Enrollment
33 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma